New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.

Antitumor necrosis factor α agents have dramatically changed the management of inflammatory bowel disease (IBD). However, a significant proportion of patients does not respond or lose response over time. Hence, there is an urgent need for new molecules, with different mechanisms of action, and with a targeted and more effective approach. These new drugs include either small molecules or biological agents. We describe the three most promising classes of molecules in the field of IBD: anti-adhesion, anti-interleukin 12/23 and anti-Janus Kinases therapies.
AuthorsIvana Bravatà, Gionata Fiorino, Mariangela Allocca, Alessandro Repici, Silvio Danese
JournalScandinavian journal of gastroenterology (Scand J Gastroenterol) Vol. 50 Issue 1 Pg. 113-20 (Jan 2015) ISSN: 1502-7708 [Electronic] England
PMID25523561 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Cell Adhesion Molecules
  • Immunosuppressive Agents
  • Interleukin-23
  • Interleukin-12
  • Janus Kinases
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Cell Adhesion Molecules (antagonists & inhibitors)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Inflammatory Bowel Diseases (drug therapy, immunology)
  • Interleukin-12 (antagonists & inhibitors)
  • Interleukin-23 (antagonists & inhibitors)
  • Janus Kinases (antagonists & inhibitors)
  • Molecular Targeted Therapy (methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: